Samsung Biologics Co.,Ltd. (207940.KS), a contract development and manufacturing organization, on Wednesday reported profit before tax of 574.579 billion won for the fourth quarter, up 59.4% from 360.492 billion won in the same period a year earlier.
Operating profit increased 67.8% to 528.251 billion won from 314.746 billion won a year earlier.
Net income attributable to shareholders rose 74.1% to 453.050 billion won from 260.256 billion won in the same period last year.
Sales climbed 35.3% to 1,285.706 billion won from 950.351 billion won a year earlier.
Excluding potential contributions from the planned acquisition of the U.S. site, the company projects 15-20% annual revenue growth for 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.